Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
about
Allopurinol: insights from studies of dose-response relationships.Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effectPharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.Quality of care indicators for gout management.Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.Allopurinol reduces antigen-specific and polyclonal activation of human T cells.Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patientsPathophysiology, clinical presentation and treatment of gout.Management of gout.The history and future of probenecid.Allopurinol hypersensitivity syndrome: a review.Utilization of allopurinol in the Australian community.Appropriate dosing regimen of allopurinol in Japanese patients.Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.The population pharmacokinetics of allopurinol and oxypurinol in patients with gout
P2860
Q30240163-B6C8ADB7-AC3E-42E4-8291-BEDB59D77405Q33973851-3B191816-DB41-457F-81BB-635AEC96D248Q34358401-23A7A9A1-30AD-4142-A2DF-EC8CB66D7FE2Q34587063-06DEB786-DDA8-42C5-A71F-9D2BF3B5ED9CQ34656225-749CF240-694F-4DB7-A23C-B10A9297FE25Q35691678-9C861A79-4AE3-482B-BD7C-30BCA025844DQ36013873-E868042C-4EEB-4309-8BC5-704328D5746AQ36250232-C43E5ACE-D84A-4ACD-8709-D245165F00B4Q36508689-DA51E8FB-EA8E-421D-944B-3353A94D2B53Q36586895-66103F23-14C1-40B8-A90B-645CC4F4ADC5Q37139512-55F70E47-B294-454B-941C-79B3CEB78210Q37936912-19E2F7C0-F3D9-4CFA-BC02-BCACA5B47DA1Q40720543-894F4005-C9D1-4DDE-93C1-159645BB64DDQ44403105-066F6163-E424-44B6-A33A-5ACDA1E0EEDDQ46572298-DFDB8F68-2A96-42D1-84E1-1C23A5FB2EE6Q46980770-728FA37E-6713-4A83-9A68-0782232D38F0Q57154764-21A2A47A-F330-45EA-85DF-652C63309C47
P2860
Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
description
1988 nî lūn-bûn
@nan
1988 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Allopurinol dosage selection: ...... s and urinary urate excretion.
@ast
Allopurinol dosage selection: ...... s and urinary urate excretion.
@en
Allopurinol dosage selection: ...... s and urinary urate excretion.
@nl
type
label
Allopurinol dosage selection: ...... s and urinary urate excretion.
@ast
Allopurinol dosage selection: ...... s and urinary urate excretion.
@en
Allopurinol dosage selection: ...... s and urinary urate excretion.
@nl
prefLabel
Allopurinol dosage selection: ...... s and urinary urate excretion.
@ast
Allopurinol dosage selection: ...... s and urinary urate excretion.
@en
Allopurinol dosage selection: ...... s and urinary urate excretion.
@nl
P2093
P2860
P1476
Allopurinol dosage selection: ...... s and urinary urate excretion.
@en
P2093
Birkett DJ
Whitehead A
P2860
P304
P356
10.1111/J.1365-2125.1988.TB03401.X
P407
P577
1988-10-01T00:00:00Z